{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:12:55Z","timestamp":1792141975498,"version":"4.4.0"},"reference-count":49,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:00:00Z","timestamp":1615593600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2021,7,30]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Spinal muscular atrophy (SMA) is a rare neurodegenerative disease characterized by progressive muscular weakness, which occurs in one in 6,000 to 10,000 live births. The burden of SMA on Canadian patients and caregivers is not known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To characterize the burden of SMA in Canada as reported by patients and caregivers, including disease and treatment impacts, indirect costs, and caregiver burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Surveys were distributed by Cure SMA Canada and Muscular Dystrophy Canada to individuals with SMA and their caregivers. The online surveys were anonymous and completed between January 28 and February 21, 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>965 patient and 962 caregiver responses met the eligibility criteria. Patients reported SMA subtypes as: type I (25.0%), type II (41.3%), type III (29.3%). Using the EQ-5D, patients were shown to have impaired quality of life with an average health utility index of 0.49 (SD: 0.26). The median expenditure was $4,500 CAD (IQR: $1,587 \u2013 $11,000) for assistive devices; $6,800 CAD (IQR: $3,900\u2013$13,000) on health professional services; and $1,200 CAD (IQR: $600 \u2013$3,100) on SMA-related travel and accommodation in the past 12 months. Caregivers reported needing respite care (45.7%), physiotherapy for an injury from a lift\/transfer (45.7%), or other health impacts (63.3%). Caregivers reported changes to personal plans, sleep disturbances, and work adjustments, with a mean Caregiver Strain Index score of 7.5 [SD: 3.3].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>SMA in Canada is associated with a significant burden for patients and their caregivers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jnd-200610","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T14:24:54Z","timestamp":1615904694000},"page":"553-568","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":55,"title":["Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada"],"prefix":"10.1177","volume":"8","author":[{"given":"H.J.","family":"McMillan","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gerber","sequence":"additional","affiliation":[{"name":"Medlior Health Outcomes Research Ltd., Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Cowling","sequence":"additional","affiliation":[{"name":"Medlior Health Outcomes Research Ltd., Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Khuu","sequence":"additional","affiliation":[{"name":"Medlior Health Outcomes Research Ltd., Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Medlior Health Outcomes Research Ltd., Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Wu","sequence":"additional","affiliation":[{"name":"Hoffmann-La Roche Limited, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Maturi","sequence":"additional","affiliation":[{"name":"Hoffmann-La Roche Limited, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Klein-Panneton","sequence":"additional","affiliation":[{"name":"Hoffmann-La Roche Limited, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cabalteja","sequence":"additional","affiliation":[{"name":"Hoffmann-La Roche Limited, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lochm\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada"},{"name":"Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada"},{"name":"Brain and Mind Research Institute, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,3,13]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23616"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2010.03.001"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60921-6"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.10425"},{"key":"ref006","unstructured":"Isaac Foundation for Rare Diseases. Spinal Muscular Atrophy (SMA) - A Resource for Canadian Families Battling SMA. Available from: https:\/\/www.theisaacfoundation.com\/sma\/."},{"key":"ref007","unstructured":"ChenG, SharifB, GerberB, FarrisM, CowlingT, CabaltejaC, WuJ, MaturiB, Klein-PannetonK, MahJ. A population-based study examining the epidemiologic burden, healthcare resource utilization and costs of spinal muscular atrophy in Alberta, Canada. 25th International Annual Congress of the World Muscle Society; 2020. October 1, 2020; Virtual Congress."},{"key":"ref008","unstructured":"Statistics Canada. Table 17-10-0009-01 Population estimates, quarterly."},{"key":"ref009","unstructured":"MahJK, HaigT, HodgkinsonV, InnesM, KorngutL, ParboosinghJ. 5q spinal muscular atrophy. January 22, 2021. Available from: https:\/\/www.cpsp.cps.ca\/uploads\/studies\/5q-spinal-muscular-atrophy-protocol.pdf."},{"key":"ref010","unstructured":"Muscular Dystrophy Canada. Statement from Stacey Lintern, \nChief Executive Officer, Muscular Dystrophy Canada on a Collaboration with Novartis for National Newborn Screening in Spinal Muscular Atrophy (SMA); 2020.Available from: https:\/\/muscle.ca\/2020\/12\/04\/mdc-statement\/."},{"key":"ref011","unstructured":"The Neuromuscular Disease Network for Canada \n(NMD4C). A national spinal muscular atrophy registry for real world evidence; 2020. Available from: https:\/\/neuromuscularnetwork.ca\/news\/a-national-spinal-muscular-atrophy-registry-for-real-world-evidence\/."},{"key":"ref012","unstructured":"Canadian Institute for Health Information. Health Care Cost Drivers: The Facts. Ottawa, Ontario, Canada: Canadian Institute for Health Information; 2011."},{"key":"ref013","unstructured":"Institute of Health Economics. IHE In Your Pocket 2014: A Handbook of Health Economic Statistics: Institute of Health Economics; 2014. Available from: https:\/\/www.ihe.ca\/advanced-search\/ihe-in-your-pocket-2014-a-handbook-of-health-economic-statistics."},{"key":"ref014","unstructured":"Health Canada. Canada\u2019s Health Care System. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/health-care-system\/reports-publications\/health-care-system\/canada.html."},{"key":"ref015","first-page":"1","volume":"15","author":"Marchildon GP","year":"2013","journal-title":"Health Systems in Transition"},{"key":"ref016","unstructured":"Canada Revenue Agency. Disability-Related Information. February 4, 2021. Available from: https:\/\/www.canada.ca\/en\/revenue-agency\/services\/forms-publications\/publications\/rc4064\/disability-related-information-2016.html."},{"key":"ref017","unstructured":"Canadian Institute for Health Information. National Health Expenditure Trends 1975 to 2019. Ottawa, ON: Canadian Institute for Health Information; 2019."},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0424-0"},{"key":"ref019","unstructured":"Health Canada. Regulatory Decision Summary - Spinraza 2017. Available from: https:\/\/hpr-rps.hres.ca\/reg-content\/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00268."},{"key":"ref020","unstructured":"Muscular Dystrophy Canada. Spinraza Decision Signals the Need for a Canadian Rare Disease (or Orphan Drug) Framework; 2019. Available from: https:\/\/muscle.ca\/2019\/03\/08\/cadth-review-and-spinraza\/."},{"key":"ref021","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Common Drug Review: Canadian Drug Expert Committee Recommendation - Nusinersen (Spinraza - Biogen Canada Inc.); 2019. January 22, 2021. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/complete\/SR0576-Spinraza-Resubmission-Mar-1-19.pdf."},{"key":"ref022","unstructured":"Health Canada. Regulatory Decision Summary - Zolgensma. 2020."},{"key":"ref023","unstructured":"Hoffmann-La Roche. Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA); 2020. Available from: https:\/\/www.roche.com\/media\/releases\/med-cor-2020-09-28.htm."},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020907"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.02.011"},{"key":"ref026","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0695-0"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2014.01.037"},{"key":"ref028","unstructured":"Qualtrics. Fraud Detection 2020. Available from: https:\/\/www.qualtrics.com\/support\/survey-platform\/survey-module\/survey-checker\/fraud-detection\/."},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.1758"},{"key":"ref030","unstructured":"EuroQol Research Foundation. EQ-5D-5L | About 2017. Available from: https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/."},{"key":"ref031","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000447"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1093\/geronj\/38.3.344"},{"key":"ref033","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180342"},{"key":"ref034","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000741"},{"key":"ref035","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25101"},{"key":"ref036","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25148"},{"key":"ref037","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990815)86:4<577::AID-CNCR6>3.0.CO;2-S"},{"key":"ref038","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8549-1"},{"key":"ref039","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70061-3"},{"key":"ref040","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1646263"},{"key":"ref041","first-page":"92","author":"Goble J","year":"2019","journal-title":"Neurology"},{"key":"ref042","doi-asserted-by":"publisher","DOI":"10.36469\/63185"},{"issue":"1","key":"ref043","first-page":"21","volume":"12","author":"Shields M","year":"2000","journal-title":"Health Rep"},{"key":"ref044","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01325-z"},{"key":"ref045","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"ref046","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.004"},{"key":"ref047","unstructured":"FDA NEWS RELEASE: FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality [press release]. May 24, 2019."},{"key":"ref048","unstructured":"WexlerM. Zolgensma Approved to Treat Young SMA Patients in Canada 2020. Available from: https:\/\/smanewstoday.com\/news-posts\/2020\/12\/18\/zolgensma-approved-pediatric-sma-patients-health-canada\/."},{"key":"ref049","unstructured":"FDA NEWS RELEASE: FDA Approves Oral Treatment for Spinal Muscular Atrophy [press release]. August 7, 2020."}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-200610","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JND-200610","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-200610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:40Z","timestamp":1777506580000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JND-200610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,13]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7,30]]}},"alternative-id":["10.3233\/JND-200610"],"URL":"https:\/\/doi.org\/10.3233\/jnd-200610","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,13]]}}}